<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="lead">
            <roleset id="lead.01" name="resulted&#x0A;" wordnet="3">
                <roles>
                    <role n="0" descr="factors&#x0A;" />
                    <role n="1" descr="result&#x0A;" />
                </roles>
                <example src="EMBO" no="0">
                    <text>Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D leads to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).</text>
                    <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D</arg>
                    <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).</text>
                    <arg n="0">inactivation of the MEF2C gene</arg>
                    <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5</arg>
                </example>
                <example src="EMBO" no="2">
                    <text>These data suggest that phosphorylation of the MuSK NPXY site leads to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.</text>
                    <arg n="0">phosphorylation of the MuSK NPXY site</arg>
                    <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein</arg>
                </example>
                <example src="EMBO" no="3">
                    <text>This G:C base pair is also the strongest determinant in the sequence selection experiment, which led to the identification of the BRE (Lagrange et al., 1998).</text>
                    <arg n="0">the sequence selection experiment</arg>
                    <arg n="1">the identification of the BRE</arg>
                </example>
                <example src="EMBO" no="4">
                    <text>This, in turn, leads to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.</text>
                    <arg n="0">This</arg>
                    <arg n="1">synergistic activation of the ANF and other MEF2 target promoters</arg>
                </example>
                <example src="MEDLINE" no="1">
                    <text>By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (7 missense mutations, 2 mutations leading to frameshift, and 1 mutation predicted to affect normal splicing).</text>
                    <arg n="0">7 missense mutations, 2 mutations</arg>
                    <arg n="1">frameshift</arg>
                </example>
                <example src="MEDLINE" no="2">
                    <text>Disruption of the SNU246 gene in yeast is lethal and leads to a splicing defect in vivo, indicating that the protein is essential for splicing.</text>
                    <arg n="0">Disruption of the SNU246 gene in yeast</arg>
                    <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing</arg>
                </example>
                <example src="MEDLINE" no="3">
                    <text>G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).</text>
                    <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14</arg>
                    <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)</arg>
                </example>
                <example src="MEDLINE" no="4">
                    <text>Genetic deficiency of GM2 activator leads to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).</text>
                    <arg n="0">Genetic deficiency of GM2 activator</arg>
                    <arg n="1">a neurological disorder</arg>
                </example>
                <example src="MEDLINE" no="5">
                    <text>In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5 splicing site of the third intron, which inactivates the 5 cleavage event of splicing and leads to ligation of the second to the fourth exon.</text>
                    <arg n="0">a point mutation at the 5 splicing site of the third intron</arg>
                    <arg n="1">ligation of the second to the fourth exon</arg>
                </example>
                <example src="MEDLINE" no="6">
                    <text>The mutations identified include: two frameshifts and a splice site mutation leading to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, two of which involve amino acids located within putative transmembrane domains.</text>
                    <arg n="0">two frameshifts and a splice site mutation</arg>
                    <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations</arg>
                </example>
                <example src="MEDLINE" no="7">
                    <text>The splice mutation in 5 end of intron 5 leading to abnormal splice in exon 5 and exon 6 appears to be one of the causes of X-linked recessive adrenoleukodystrophy.</text>
                    <arg n="0">The splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="MEDLINE" no="8">
                    <text>These results suggest that the distinct amino termini lead to the targeting of individual VDAC isoforms to different cellular compartments.</text>
                    <arg n="0">the distinct amino termini</arg>
                    <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments</arg>
                </example>
                <example src="MEDLINE" no="9">
                    <text>This leads to a substantial diversity of nebulin and nebulette isoforms.</text>
                    <arg n="0">This</arg>
                    <arg n="1">a substantial diversity of nebulin and nebulette isoforms</arg>
                </example>
                <example src="MEDLINE" no="10">
                    <text>This patients DNA contains a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele that is detectably expressed, leading to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.</text>
                    <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele</arg>
                    <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein</arg>
                </example>
                <example src="MEDLINE" no="11">
                    <text>This splice mutation in 5 end of intron 5 might lead to abnormal splice in exon 5 and exon 6 and bring about unstable and abnormal ALD protein; the lignoceryl CoA ligase could not transport very long chain fatty acids (VLCFA) into peroxisome and could not function normally; consequently, defective beta-oxidation of VLCFA in peroxisome could result in an accumulation of VLCFAS in the central nervous system, adrenal gland and blood.</text>
                    <arg n="0">This splice mutation in 5 end of intron 5</arg>
                    <arg n="1">abnormal splice in exon 5 and exon 6</arg>
                </example>
                <example src="MEDLINE" no="12">
                    <text>This was caused by a point mutation (GTC----ATC) at codon 383, which leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.</text>
                    <arg n="0">a point mutation (GTC----ATC) at codon 383</arg>
                    <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter</arg>
                </example>
                <example src="MEDLINE" no="13">
                    <text>We also studied in detail a complex splice site mutation, 3332dupl8bp, which was shown to lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.</text>
                    <arg n="0">a complex splice site mutation</arg>
                    <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
